AEON Biopharma, Inc. (AEON) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00791X2099
AEON Biopharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -12.80 m USD |
| EBIT | -39.22 m USD |
| Net income | -39.22 m USD |
| Diluted EPS – continuing operations | -3.95 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
More stocks
- Concrete Leveling Systems Inc (CLEV)
- Sintx Technologies, Inc. (SINT)
- Trio Petroleum Corp (TPET)
- Lifeward Ltd. (LFWD)
- Lexaria Bioscience Corp. (LEXX)
- AVALON HOLDINGS CORP (AWX)
- Cellectar Biosciences, Inc. (CLRB)
- Dare Bioscience, Inc. (DARE)
- Volato Group, Inc. (SOAR)
- FGI Industries Ltd. (FGI)
- Greenland Technologies Holding Corp. (GTEC)
- Wetouch Technology Inc. (WETH)
Not investment advice. All data without warranty, price as of 18.11.2026. Details in the risk notice.